Clear

Search Results Within Category "Prevention"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
4results

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

clinicaltrials@northshore.org

ALL
18 years to 75 years old
PHASE2
This study is NOT accepting healthy volunteers
NCT06143956
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Have a body mass index (BMI) ≥27 kg/m² * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss.
Exclusion Criteria:
* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure. * Have a history of symptomatic gallbladder disease within the past 2 years. * Have a lifetime history of suicide attempts.
DRUG: LY3305677, DRUG: LY3841136, DRUG: Tirzepatide, DRUG: Placebo, DRUG: LY3549492
Obesity, Overweight
I'm interested

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

clinicaltrials@northshore.org

ALL
18 years to 75 years old
PHASE2
This study is NOT accepting healthy volunteers
NCT06230523
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
W8M-MC-LAA1 * Are males and females who agree to abide by the reproductive and contraceptive requirements W8M-MC-CWMM: * Have a BMI ≥27 kg/m² * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-LAA1 * Have any prior diagnosis of diabetes mellitus except gestational diabetes. * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure (CHF). * Have a history of acute or chronic pancreatitis. * Have an on-going or history of bradyarrhythmia and/or sinus bradycardia at screening and baseline. W8M-MC-CWMM * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a lifetime history of suicide attempts.
DRUG: LY3841136, DRUG: Placebo
Obesity, Overweight and Obesity
Overnutrition, Hormones, Chronic weight management
I'm interested

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

clinicaltrials@northshore.org

ALL
18 years to 75 years old
PHASE2
This study is NOT accepting healthy volunteers
NCT06603571
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening W8M-MC-CWMM: * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-LAA2 * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Have an on-going or history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2 * Have a history of acute or chronic pancreatitis * Have fasting triglycerides \>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening * All concomitant medications should be at a stable dose for at least 3 months prior to screening W8M-MC-CWMM * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a lifetime history of suicide attempts.
DRUG: LY3841136, DRUG: Tirzepatide, DRUG: Placebo
Obesity, Overweight
Type 2 Diabetes
I'm interested

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

clinicaltrials@northshore.org

ALL
18 years to 75 years old
PHASE2
This study is NOT accepting healthy volunteers
NCT06683508
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
W8M-MC-GN01: * Assigned male at birth * Assigned female at birth, who are of non-childbearing potential W8M-MC-CWMM: * Have a BMI ≥27 kilograms per square meter (kg/m²) * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
Exclusion Criteria:
W8M-MC-GN01: * Have Type 2 Diabetes Mellitus or Type 1 Diabetes Mellitus * Have a history of acute or chronic pancreatitis * Have renal impairment * Individuals who are of childbearing potential W8M-MC-CWMM: * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have any of the following cardiovascular conditions within 3 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure. * Have a history of symptomatic gallbladder disease within the past 2 years * Have a lifetime history of suicide attempts.
DRUG: LY3549492, DRUG: Placebo
Obesity, Overweight
I'm interested